Related Experiment Video

Updated: May 20, 2026

Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

Loss of dicer exacerbates cyclophosphamide-induced bladder overactivity by enhancing purinergic signaling

Shu Zhang1, Jian-Wei Lv, Ping Yang

  • 1The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Insights

MicroRNAs (miRNAs) play a crucial role in overactive bladder (OAB). Loss of miRNAs exacerbates OAB symptoms by increasing P2X expression, highlighting their protective function in purinergic signaling.

Area of Science:

  • Urology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) regulate gene expression in various pathologies.
  • The role of miRNAs in the pathoetiology of overactive bladder (OAB) is largely unknown.

Purpose of the Study:

  • To investigate the impact of miRNA processing on OAB development and characteristics.
  • To elucidate the role of Dicer-dependent miRNAs in regulating detrusor function and OAB pathogenesis.

Main Methods:

  • Generated a mouse model with inducible Dicer deletion in the detrusor muscle.
  • Induced OAB using cyclophosphamide and assessed detrusor function, urodynamics, and macrophage infiltration.
  • Analyzed miRNA targeting of P2x mRNAs and P2X expression in detrusor tissue.
  • Examined human OAB patient bladder biopsies for similar molecular changes.

Main Results:

  • Dicer deletion alone did not significantly alter detrusor function under physiological conditions.
  • Loss of Dicer exacerbated cyclophosphamide-induced OAB, showing increased severity in contractile force, sensitivity, abnormal urodynamics, and macrophage infiltration.
  • Dicer deficiency led to impaired miRNA expression targeting P2x mRNAs, resulting in enhanced P2X expression in the detrusor.
  • Similar findings were observed in human OAB patient bladder biopsies, indicating conserved mechanisms.

Conclusions:

  • miRNAs modulate OAB susceptibility by regulating purinergic signaling pathways.
  • Loss of Dicer impairs miRNA-mediated suppression of P2X expression, predisposing to OAB.
  • These findings suggest a protective role for specific miRNAs in suppressing OAB symptoms via purinergic signaling regulation.

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...